Early neonatal diagnosis of long-chain 3-hydroxyacyl coenzyme A dehydrogenase and mitochondrial trifunctional protein deficiencies

被引:35
作者
Hintz, SR
Matern, D
Strauss, A
Bennett, MJ
Hoyme, HE
Schelley, S
Kobori, J
Colby, C
Lehman, NL
Enns, GM
机构
[1] Stanford Univ, Div Neonatal & Dev Med, Palo Alto, CA 94304 USA
[2] Stanford Univ, Dept Pediat, Palo Alto, CA 94304 USA
[3] Stanford Univ, Dept Pathol, Palo Alto, CA 94304 USA
[4] Mayo Clin, Div Lab Genet, Dept Lab Med & Pathol, Rochester, MN USA
[5] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37212 USA
[6] Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX USA
[7] Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX USA
[8] Kaiser Permanente Hosp, Div Genet, San Jose, CA USA
关键词
D O I
10.1006/mgme.2001.3282
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tandem mass spectrometry (MS/MS) has been introduced in several newborn screening programs for the detection of a large number of inborn errors of metabolism, including fatty acid oxidation disorders (FAOD). Early identification and treatment of FAOD have the potential to improve outcome and may be life-saving in some cases; an estimated 5% of sudden infant deaths are attributable to undiagnosed disorders of fatty acid oxidation. We report very early neonatal presentations of long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) and mitochondrial trifunctional protein (TFP) deficiencies confirmed by molecular analysis. Both patients had cardiorespiratory collapse and hypoglycemia, without a history of maternal pregnancy complications. Retrospective MS/MS analysis of the original newborn screening blood spots revealed characteristic acylcarnitine profiles. These cases are among the earliest reported presentations of LCHAD and TFP deficiencies and further illustrate the potential of MS/MS as a valuable tool for newborn screening of FAOD. However, timely analysis and reporting of results to clinicians are essential, because these disorders can manifest in the first few days of life. (C) 2002 Elsevier Science (USA).
引用
收藏
页码:120 / 127
页数:8
相关论文
共 32 条
[1]   Inborn errors of mitochondrial fatty acid oxidation [J].
Bennett, MJ ;
Rinaldo, P ;
Strauss, AW .
CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2000, 37 (01) :1-44
[2]   Mitochondrial short-chain L-3-hydroxyacyl-coenzyme a dehydrogenase deficiency: A new defect of fatty acid oxidation [J].
Bennett, MJ ;
Weinberger, MJ ;
Kobori, JA ;
Rinaldo, P ;
Burlina, AB .
PEDIATRIC RESEARCH, 1996, 39 (01) :185-188
[3]  
Bennett MJ, 2001, CLIN CHEM, V47, P1145
[4]   Arrhythmias and conduction defects as presenting symptoms of fatty acid oxidation disorders in children [J].
Bonnet, D ;
Martin, D ;
de Lonlay, P ;
Villain, E ;
Jouvet, P ;
Rabier, D ;
Brivet, M ;
Saudubray, JM .
CIRCULATION, 1999, 100 (22) :2248-2253
[5]  
Chace DH, 2001, CLIN CHEM, V47, P1166
[6]   Trifunctional protein deficiency: Three families with significant maternal hepatic dysfunction in pregnancy not associated with E474Q mutation [J].
Chakrapani, A ;
Olpin, S ;
Cleary, M ;
Walter, JH ;
Wraith, JE ;
Besley, GTN .
JOURNAL OF INHERITED METABOLIC DISEASE, 2000, 23 (08) :826-834
[7]   3-HYDROXYDICARBOXYLIC ACIDURIA DUE TO LONG-CHAIN 3-HYDROXYACYL-COENZYME-A DEHYDROGENASE-DEFICIENCY ASSOCIATED WITH SUDDEN NEONATAL DEATH - PROTECTIVE EFFECT OF MEDIUM-CHAIN TRIGLYCERIDE TREATMENT [J].
DURAN, M ;
WANDERS, RJA ;
DEJAGER, JP ;
DORLAND, L ;
BRUINVIS, L ;
KETTING, D ;
IJLST, L ;
VANSPRANG, FJ .
EUROPEAN JOURNAL OF PEDIATRICS, 1991, 150 (03) :190-195
[8]   Mitochondrial respiratory chain complex I deficiency with clinical and biochemical features of long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency [J].
Enns, GM ;
Bennett, MJ ;
Hoppel, CL ;
Goodman, SI ;
Weisiger, K ;
Ohnstad, C ;
Golabi, M ;
Packman, S .
JOURNAL OF PEDIATRICS, 2000, 136 (02) :251-254
[9]   Dietary management of long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD). A case report and survey [J].
Gillingham, M ;
Van Calcar, S ;
Ney, D ;
Wolff, J ;
Harding, C .
JOURNAL OF INHERITED METABOLIC DISEASE, 1999, 22 (02) :123-131
[10]  
HANNON HW, 2001, MMWR-MORBID MORTAL W, V50, P1